The Effect Of Doluxetine On The Treatment Of Neuropathy Induced By Paclitaxol In Breast Cancer Patients
Phase 3
Recruiting
- Conditions
- breast cancer.Malignant neoplasm of breast
- Registration Number
- IRCT20180805040700N1
- Lead Sponsor
- Arak University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 80
Inclusion Criteria
Persons over 18 years of age
Good co-operation
Patients with breast cancer under the first course of paclitaxel therapy
People under the age of 75
Exclusion Criteria
intolerance of duloxetine
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method europathy. Timepoint: first referral of patients and 12 weeks after start intervention. Method of measurement: Patient Neurotoxicity Questionnaire = PNQ, EMG-NCV of the four limbs Amplitude and latency analysis of mental and movement neurals of lower and lower fever.
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie duloxetine's efficacy in mitigating paclitaxel-induced neuropathy in breast cancer patients?
How does duloxetine compare to standard-of-care treatments like gabapentin for chemotherapy-induced peripheral neuropathy in phase III trials?
Which biomarkers correlate with duloxetine response in breast cancer patients experiencing paclitaxel-induced neurotoxicity?
What adverse events are reported in phase III trials of duloxetine for paclitaxel-induced neuropathy, and how are they managed?
Are there combination therapies involving duloxetine and neuroprotective agents that enhance outcomes in breast cancer chemotherapy?